MedPath

The First Affiliated Hospital of Nanchang University

🇨🇳China
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.cdyfy.com

Clinical Trials

29

Active:1
Completed:4

Trial Phases

5 Phases

Early Phase 1:1
Phase 1:4
Phase 2:4
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials

Not Applicable
11 (45.8%)
Phase 1
4 (16.7%)
Phase 2
4 (16.7%)
Phase 4
4 (16.7%)
Early Phase 1
1 (4.2%)

Comparison of Short- and Long-term Outcomes Between Robotic and Laparoscopic Hemicolectomy of Right Colon Cancer : A Multicenter Propensity Score Matching Analysis

Not yet recruiting
Conditions
Robotic Surgical Procedures
Right Colon Tumors
Cancer
Laparoscopic Abdominal Surgery
First Posted Date
2025-06-19
Last Posted Date
2025-06-19
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
4000
Registration Number
NCT07029464

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

Early Phase 1
Recruiting
Conditions
Relapsed/Refractory
Multiple Myeloma
Interventions
Biological: BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell
First Posted Date
2025-05-31
Last Posted Date
2025-05-31
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
12
Registration Number
NCT06999031
Locations
🇨🇳

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment

Not Applicable
Recruiting
Conditions
Colorectal Cancer (CRC)
Interventions
First Posted Date
2024-12-30
Last Posted Date
2024-12-30
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
10
Registration Number
NCT06751966
Locations
🇨🇳

First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

🇨🇳

The First Hospital of Nanchang, Nanchang, Jiangxi, China

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Not Applicable
Recruiting
Conditions
Advanced NSCLC
Interventions
Radiation: Radiotherapy
Drug: PD-1 inhibitor
First Posted Date
2024-12-30
Last Posted Date
2024-12-30
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
10
Registration Number
NCT06752057
Locations
🇨🇳

First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

🇨🇳

The First Hospital of Nanchang, Nanchang, Jiangxi, China

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Phase 2
Recruiting
Conditions
Advanced NSCLC
Interventions
Radiation: Radiotherapy
Drug: PD-1 inhibitor
First Posted Date
2024-12-30
Last Posted Date
2024-12-30
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
10
Registration Number
NCT06751901
Locations
🇨🇳

First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

🇨🇳

The First Hospital of Nanchang, Nanchang, Jiangxi, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.